Our experiment with a small sample preliminarily confirmed that serum nucleolin+ TEVs are potential biomarkers for NPC detection and that changes in PD-L1+ TEVs levels are potential predictive biomarkers for immune checkpoint blockade therapy responses. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.